COMP <GO>
DXCM vs MDLN // EV/EBITDA & P/E VALUATION
DexCom Inc. (NASDAQ) VS. Medline Inc. (NASDAQ) • 15-METRIC TALLY: DXCM 7
— MDLN 4
▲ EV/EBITDA & P/E VALUATION LEADER: MDLN
LAST: $82.29 (+2.95%) • MKT CAP: $30.16B
valuation
25.2x
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
valuation
20.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DXCM VS. MDLN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DXCM | MDLN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.60% | 8.20% | +13.40 | DXCM | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 25.2x | 20.3x | +4.90 | MDLN | /valuation <GO> |
| Free Cash Flow Yield | 3.57% | 3.08% | +0.49 | DXCM | /fcf-yield <GO> |
| Operating Margin | 19.60% | 7.80% | +11.80 | DXCM | /operating-margins <GO> |
| Net Profit Margin | 17.90% | 68.00% | -50.10 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 15.60% | 11.50% | +4.10 | DXCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.14 | 2.50 | +4.64 | DXCM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | DXCM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 30.9 | +10.90 | DXCM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.11 | -0.01 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $30.16B | $42.07B | -$11.91B | MDLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DXCM REV | MDLN REV | DXCM GROSS % | MDLN GROSS % | DXCM FCF | MDLN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.66B | $28.43B | 60.1% | 26.4% | $1.08B | $1.30B |
| FY 2024 | $4.03B | $25.51B | 60.5% | 27.3% | $630.7M | $1.42B |
| FY 2023 | $3.62B | $23.23B | — | — | $585.5M | $639.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DXCM // BETA 1.10
MDLN // BETA 1.11